Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of applied clinical medical physics"
DOI: 10.1002/acm2.13899
Abstract: Prostate-specific membrane antigen (PSMA) is a cell surface protein highly expressed in nearly all prostate cancers, with restricted expression in some normal tissues. The differential expression of PSMA from tumor to non-tumor tissue has resulted… read more here.
Keywords: prostate specific; radiopharmaceutical therapy; therapy; program ... See more keywords
Special issue “The advance of solid tumor research in China”: 68Ga‐PSMA‐11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34189
Abstract: Conventional imaging examinations are not sensitive enough for the early detection of recurrent or metastatic lesions in renal cell carcinoma (RCC) patients. We aimed to explore the role of 68Ga‐prostate specific membrane antigen (PSMA)‐11 positron… read more here.
Keywords: cell; pet; 68ga psma; psma ... See more keywords
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Radiation Sciences"
DOI: 10.1002/jmrs.227
Abstract: Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for… read more here.
Keywords: psma; prostate cancer; men prostate; cancer ... See more keywords
Intracellular Delivery of Glucose Oxidase for Enhanced Cytotoxicity toward PSMA-Expressing Prostate Cancer Cells.
Sign Up to like & getrecommendations! Published in 2019 at "Macromolecular bioscience"
DOI: 10.1002/mabi.201900183
Abstract: Reactive oxygen species (ROS) forming enzymes are of significant interest as anticancer agents due to their potent cytotoxicity. A key challenge in their clinical translation is attaining site-specific delivery and minimizing biodistribution to healthy tissues.… read more here.
Keywords: delivery; glucose oxidase; pll peg; cancer ... See more keywords
A Renal-Clearable Activatable Molecular Probe for Fluoro-Photacoustic and Radioactive Imaging of Cancer Biomarkers.
Sign Up to like & getrecommendations! Published in 2022 at "Small"
DOI: 10.1002/smll.202201334
Abstract: In vivo simultaneous visualization of multiple biomarkers is critical to accurately diagnose disease and decipher fundamental processes at a certain pathological evolution, which however is rarely exploited. Herein, a multimodal activatable imaging probe (P-125 I)… read more here.
Keywords: renal clearable; prostate cancer; clearable activatable; psma ... See more keywords
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3743-z
Abstract: PurposePET/CT using 68Ga-labelled prostate-specific membrane antigen PSMA-11 (HBEDD-CC) has emerged as a promising imaging method in the diagnostic evaluation of prostate cancer (PC) patients with biochemical recurrence. However, assessment of local recurrence (LR) may be… read more here.
Keywords: pet; recurrence; early pet; local recurrence ... See more keywords
Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-017-3903-1
Abstract: An osteoid osteoma (OO) is a rare osteoblastic benign bone tumor representing approximately 14% of all bone tumors. It usually arises from cortico-diaphyseal and metaphyseal regions of long bones, mostly in the lower limbs, and… read more here.
Keywords: computed tomography; pet; psma pet; incidental identification ... See more keywords
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4079-z
Abstract: PurposeSince the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC… read more here.
Keywords: psma; long term; prostate cancer; psma pet ... See more keywords
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4220-z
Abstract: PurposeThe aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated 212Pb-based alpha therapy… read more here.
Keywords: ca012; alpha therapy; 203pb 212pb; dosimetry ... See more keywords
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4222-x
Abstract: BackgroundData are sparse regarding the feasibility of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited… read more here.
Keywords: psma rlt; baseline psma; rechallenge; adverse events ... See more keywords
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04612-0
Abstract: Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) never respond or develop resistance to 177Lu-labeled PSMA-targeted radioligand monotherapy. Single-agent PSMA-targeted radioligand therapy (PRLT) with the alpha-emitter 225Ac showed… read more here.
Keywords: psma 617; 177lu psma; 225ac psma; tandem therapy ... See more keywords